Depression: Beyond
Serotonin
Surprising new findings are challenging
the assumption that the world�s most common mental ailment is
"just" a chemical imbalance in the brain. The latest research
shows that the actual circuitry of the brain is impaired, even
destroyed. What�s more, the disorder appears to afflict the body as
much as the brain.
By Hara Estroff Marano
Death was now a daily presence, blowing
over me in cold gusts. Mysteriously and in ways that are totally
remote from normal experience, the gray drizzle of horror induced
by depression takes on the quality of physical pain. But it is not
an immediately identifiable pain, like that of a broken limb. It
may be more accurate to say that despair, owing to some evil trick
played upon the sick brain by the inhabiting psyche, comes to
resemble the diabolical discomfort of being imprisoned in a
fiercely overheated room. And because no breeze stirs this caldron,
because there is no escape from the smothering confinement, it is
entirely natural that the victim begins to think ceaselessly of
oblivion.
Melancholy, apparently, is a fertile muse.
No sooner had William Styron become the poet laureate of depression
after describing his bout with madness in Darkness Visible
(Random House, 1990) when all manner of confessions followed. Mike
Wallace. Art Buchwald. Dick Cavett lined up to disclose their own
struggles with the disabling disorder. It quickly became
acceptable, even chic, to publicly confide vulnerability to
depression.
At the same time, the world was being made
safe for depression, or at least public revelations of it, by
another development, the 1988 advent of the so-called SSRIs�Prozac,
Paxil and related drugs believed to specifically combat depression
by beefing up serotonin and other neurotransmitters that ferry
signals between nerve cells. The wild success of psychiatrist Peter
D. Kramer�s thoughtful Listening to Prozac (Viking) in 1993
generated not only new respect for the effectiveness of Prozac but
new appreciation of the disorder it was intended to treat.
There followed hundreds of new book titles on depression, over 100
on Prozac alone, surely making it the most heralded drug on the
planet. Depression chic cannot be dismissed as a passing fad
because, it turns out, how the disorder is defined and popularized
deeply shapes what patients are willing to do about it.
Despite the flood of Prozac prose,
depression itself has remained, as Styron saw it, a mystery. It is
one of the cruel ironies of science that it can explain the most
bizarre and rare conditions to strike us. Take Capgras� syndrome,
in which, due to an injury to the machinery for the emotional (but
not perceptual) evaluation of visual objects, people develop the
delusion that a poseur has taken the place of a loved one. But
common afflictions like depression�Western countries� second most
disabling ailment (after heart disease) and the world�s fourth�have
long eluded understanding. That, however, is beginning to
change.
In the last two or three years alone, the
refinement of brain- imaging techniques is providing an
unprecedented look into the neurobiology of depression, showing
what goes on in the brains of patients as they process positive and
negative experiences. Though just beginning, the work is
already producing a radically revised view of depression that
promises to shape new treatments for the future. Among the emerging
findings:
o Regarding depression as "just" a
"chemical imbalance" wildly misconstrues the disorder. "It is not
possible to explain either the disease or its treatment based
solely on levels of neurotransmitters," says neurobiologist Ronald
Duman, Ph.D. of Yale University.
The newest evidence indicates that
recurrent depression is in fact a neurodegenerative disorder,
disrupting the structure and function of brain cells�destroying
nerve cell connections, even killing certain brain cells, and
precipitating cognitive decline. At the very least, depression sets
up neural roadblocks to the processing of information and keeps us
from adaptively responding to whatever challenges life throws our
way.
o There does not appear to be a single
genetic cause of depression, although there does seem to be a form
of major depression that is strongly familial. Rather, the disorder
likely results from multiple biological and environmental factors.
"There may be lots of ways to get there�and lots of ways to get out
of it," says Kramer, associate professor of psychiatry at Brown
University.
o Human emotions take shape in a neural
circuit involving several key brain structures, including the
hippocampus, the amygdala, and the prefrontal cortex. In
depression, faulty circuitry begets failure both in generating
positive feelings and inhibiting disruptive negative
ones.
o Stress-related events may kick off 50%
of all depression and early life stress can prime people for later
depression. Ongoing research both in animals and in people
demonstrates that such early strain can enduringly alter
nerve circuits that control emotion, permanently exaggerating later
responses to stress and leading to the neurochemical and behavioral
changes of depression. In other words, the deeper researchers probe
the brain, the more they validate the psychoanalytic view that
early adverse life events can create adult
psychopathology.
Bold new research spanning the clinical
and the molecular ties physical and sexual abuse in childhood
to depression in adulthood via changes in the genetic
expression of brain hormones.
It's not all in the head. Depression is
not just an affliction from the neck up but a disorder involving
many body systems. It both leads to heart
disease in otherwise healthy adults and
greatly magnifies the deadliness of pre-existing cardiac problems.
What�s more, it accelerates changes in bone mass that lead to
osteoporosis. "The lifetime risk of fracture related to depression
is substantial," a team of researchers recently declared in the New
England Journal of Medicine.
oJust as nerve cell connections can be
destroyed in depression, perhaps they can be rebuilt. The common
denominator in all effective antidepressant treatments, including
electroshock, may be their ability to stimulate the sprouting of
neurons in key brain regions, literally the forging of behavioral
flexibility. A neurochemical pathway newly identified inside nerve
cells promises to revolutionize therapy by allowing for treatments
that do this better, faster, and more explicitly.
o The adult brain has a degree of
plasticity that is astonishing researchers and that promises to
revolutionize thinking about human behavior. "All these changes,
cell loss, atrophy of connections, that�s very new, and they�re
still catching people by surprise," says neurobiologist Bruce
McEwen, Ph.D., of New York�s Rockefeller University. "We thought
that after birth, the brain is a stable organ like a little
computer that just works away, and no more new nerve cells are
produced. The emphasis before was on chemical imbalances, as if the
circuitry itself was fairly stable. The big news is the structural
plasticity of the adult brain, the remodeling of neurons. The idea
that there are long-lasting, even permanent changes, in structure
and function that can affect the way our brain processes
information is the most important part of what we�re doing in the
lab."
To understand depression we have to
confront the mind/body dilemma head on. Although we often
arbitrarily divide the mind from the brain and act as if "mental
illness" were strictly mental, mood disorders are not ethereal,
disembodied ailments. If depression proves anything, the mind and
the brain are one. There are nerve circuits in the brain that color
psychological events positively and negatively, that lead us to see
rewards and pleasures or merely emptiness and hopelessness, and
then to negotiate the world either by engaging it or withdrawing
from it.
Such nerve circuits connect widely with
other brain actions, and they malfunction in depression, spreading
the malaise into every fiber of being. What sets the malfunction in
motion may be some environmental circumstances, such as neglect of
a child, or some internal physical fact, such as a faulty gene that
controls a brain enzyme. Or, likely, some highly individualistic
collision of the two.
Circuit Riding
Depression appears to hold the very soul
hostage, with total lack of energy, disturbed sleep, loss of
interest in food and sex, inability to experience pleasure,
difficulty concentrating and thinking clearly, impaired short-term
memory, self-blame, and inability to see alternatives.. But the
disorder�s full-blown misery likely arises in just a few distinct
centers in the brain. These hubs have discrete channels of
communication with each other, their messages sent out over long
filamentous arms extending from the cell bodies in one center to
those in another.
One seminal spot in the circuitry of
depression is the prefrontal cortex (PFC), the brain area just
behind the forehead, which acts as the executive branch of
emotions. According to Richard Davidson, Ph.D., professor of
psychology and psychiatry at the University of Wisconsin, two of
the PFC�s most important functions are restricted to one side or
the other. His studies show that the left side of the PFC is
crucial to establishing and maintaining positive feelings, while
the right is associated with negative ones. Depressed people appear
to have a power failure of the left PFC. The failure
shows up both in electrical studies of brain response and PET scans
indicating decreased blood flow and metabolism. The depressed
simply don�t activate the machinery to process positive emotions or
respond to positive stimuli.
Specifically, the left PFC is instrumental
in what Davidson calls "pre-goal attainment positive affect", what
you and I might call eagerness ( the positive emotion that arises
as we approach a desired goal. Depressed individuals can�t mentally
hang on to goals or keep themselves attuned to rewards. The result:
lowered capacity for pleasure, lack of motivation, loss of
interest.
But the left PFC doesn�t just activate
positive feelings. Davidson finds that it may also be crucial in
inhibiting negative emotion that gets in the way of sustaining
positive goals. In this, the left PFC draws on its connections to
the amygdala, an almond- shaped structure deep in the center of the
brain that pumps out negative feelings.
By placing experimental subjects in a
functional magnetic resonance imager to measure brain activity
while showing them emotionally laden pictures�photographs of
accidents and starving children, for example�Davidson has
graphically confirmed what many scientists have long suspected:
that the amygdala scans incoming experience for emotional
significance, puts a flag on negative feelings such as fear, and
sends out notice of threat.
If the PFC masterminds depression by
failing to activate, the amygdala controls the severity of
depression by its negative out put. Along with the University of
Pittsburgh�s Wayne C. Drevets, M.D., Davidson has found that blood
flow in the amygdala is greater the more severely depressed a
person is. Moreover, studies show that the amygdala is particularly
active during states of experimentally induced helplessness, such
as when people try to solve an unsolveable task. The activity of
the amygdala also determines how tenaciously a negative event is
held in memory.
Ordinarily, as the left PFC turns on, it
simultaneously shuts off the amygdala and dampens the flow of
negative emotions from it. But among the depressed, the general
failure of activation of the left PFC leaves the amygdala running
unchecked, overwhelming them with negative feelings.
Individuals normally differ in the degrees of
neural activation of the left and right sides of the PFC in
response to emotional messages. That difference may help account
not only for a person�s vulnerability to depression, Davidson says,
but also for variations in personality. A peppy left PFC underlies
extraversion, while a relatively more active right PFC is linked to
inhibition and anxiety. Left-sided activation prompts people to
approach situations, right-sided activation to withdraw from
them..
It isn�t clear how asymmetries in
prefrontal activity get established to begin with. "Although
these characteristics of brain function are very stable in adults,"
Davidson says, "they are much less so in children." That suggests
to him that activation levels of this circuit are set early in
life," after a sensitive period, certainly by puberty.
One clue may be that differences in PFC
activation go hand in hand with differences in brain levels of the
stress-related hormone cortisol. When the left PFC is highly
active, not only do people have a sunny outlook, their levels of
cortisol are insignificant. Cortisol patterns suggest that stress
had a hand in there somewhere.
No Glee over Glia
Barely two years ago,, Wayne Drevets, then
at Washington University, discovered that depressed persons not
only have altered PFC activity, but their prefrontal cortex is
actually smaller. It is one thing to find abnormalities in the way
the brains of the depressed function�but structural
abnormalities? Anatomical ones?
Drevets found that depressed patients have
a drastically smaller volume of a section of the left PFC that sits
about two and a half inches behind the bridge of nose and which is
called the ventral anterior cingulate. Drevets likes to call it the
subgenual prefrontal cortex because it sits beneath the genua, or
knee, of the corpus callossum, the Continental Divide of the brain.
The little site was 40% smaller in the depressed.
The subgenual cortex is vastly important:
it is one of the few cortical regions that connects with the
hypothalamus, a deep-brain structure that instigates the body�s
stress response. The subgenual cortex helps as well to
orchestrate the body�s hormonal response to stress and to
threatening stimuli. It also is the spot that helps us appreciate
that something is rewarding.
Taking their cue from Drevets� findings,
colleagues at Washington University got out their microscopes and
began looking to see what could account for the cortical shrinkage.
They examined tissue that, at autopsy, had been collected from the
brains of normal persons and those with bipolar or unipolar
depression. At the most recent meeting of the Society for
Neuroscience, graduate student Dost Ongur reported the astonishing
findings.
He had expected to see a decrease in the
number of neurons, what he calls "the business end of the brain in
terms of processing information and generating actions." Instead he
found a dramatic loss in the number of glia, small cells that
perform important�maybe critical�housekeeping functions for the
more patrician neurons. And the loss of glia was seen only in those
with a family history of depression.
Unglued by Glutamate
The glia are known to nourish neurons, by
assuring a steady supply of glucose, their preferred food. They
also protect neurons by stabilizing levels of the neurotransmitter
glutamate. Glutamate is the main transmitter in the cortex that
activates cells. Important as glutamate is, too much of it can
overstimulate neurons, causing the collapse of the branches by
which they communicate with other cells.
The glia also play a big role in the
development of the serotonin neurotransmitter system, which,
practically everyone now knows, also functions abnormally in
depression, at least in some nerve circuits. "It could be," Drevets
says, "that some defect in development of the prefrontal cortex
could be the initial abnormality in depression that starts a
cascade of changes in other systems."
It may also be that the action of
antidepressant drugs on serotonin is less important than their
action on glutamate. Researchers know that one effect of
antidepressants is to reduce the sensitivity of receptors in the
PFC for glutamate. "Suddenly," says Drevets, "that makes sense.
Agents that desensitize the frontal cortex to glutamate may be
compensating for the loss of glial cells."
Of course, that still leaves the
possibility that a serotonin deficit in other parts of the brain
could induce other depressive symptoms. But that�s exactly the
point; not only is serotonin not the whole story of depression,
neurotransmitters may not even be the main story.
Changes in the structure of the
brain�losses of cells�are relatively permanent types of alteration.
So far, there�s no evidence that such changes, once they occur�and
it�s not clear when in the lifetime course of depression they set
in�are reversed with drug or other therapy. And that may account
for the propensity of depression to recur. "What�s less clear,"
Drevets says, "is why there are periods when the illness remits,
then returns." But nature serves up at least one other example of
disorder where there are symptom-free periods despite an enduring
lesion in the brain�multiple sclerosis.
Nature, Nurture, Neuron
One of the most striking features of
depression is the inability of those afflicted to see out of their
rut, to imagine alternative ways of being and doing. "In
depression," says Yale�s Ronald Duman, associate professor of
psychiatry and pharmacology, "there�s a loss of appropriate
adaptability."
Ordinarily, the neurons of the brain have
an ability to change and adapt by sprouting new dentritic spines,
tiny fibrous protrusions that are the primary receiving end of
connections between nerve cells. By literally opening new pathways,
this sprouting is what allows us to learn and to remember, to
change our behavior, to meet new challenges, to adapt to new
circumstances. Scientists refer to this capacity as neuronal
plasticity. Depression appears to represent a failure of neuronal
plasticity.
In a ground-breaking study, Duman has
tracked the inside operations of nerve cells and found evidence
that the depressed have a deficit in specific nerve growth factors,
the substances that make possible the sprouting of new nerve cell
connections. He has implicated a reduction in brain-derived
neurotrophic factor (BDNF), a nerve growth factor specifically
known to strengthen synaptic connections in the hippocampus (a
center of learning and memory) and to enhance the growth of neurons
that respond to serotonin
Duman�s studies also show that, yet again,
how antidepressant agents are believed to work and what actually
accounts for their effectiveness may be two different things.
Long-term antidepressant treatments�including electroshock� do
increase levels of receptors for serotonin at the cell surface.
But, Duman has found, they also do something else inside the neuron
that may be more important. They kick off a cascade of molecular
steps that winds up amplifying a neuron�s own production of
BDNF�and the sprouting of new connections. Moreover, they do this
in parts of the brain that have been linked to depression, such as
the hippocampus. The real power of antidepressants, then, may be
summed up in two words: neuronal plasticity.
The molecular cascade Duman has exposed
opens up a whole new realm of possibilities for improving treatment
of depression. It may be possible to create therapies that more
directly and more strongly augment BDNF output. At the same time,
the molecular pathway culminating in BDNF production suggests new
target points for a more rapid-acting treatment of
depression.
What has Duman and others excited is that
his evidence that neuronal plasticity is at stake in depression
fits with imaging studies showing that structural changes are
taking place in the brain of the depressed. The two strands of
information suggest a way that depression might originate. In a
word: stress.
New Stress on Stress
"There is elegant work showing that
stress, whether environmental or social, actually changes the
shape, size and number of neurons in the hippocampus," says Duman.
"There are studies showing that stress decreases levels of BDNF.
It�s a really hot area of research right now." And right at its
epicenter is Bruce McEwen, head of the neurobiology laboratory at
Rockefeller and of the MacArthur Foundation work group on the
relationship of socioeconomic status and health.
In the lab, McEwen is studying what
happens in the adult brain of animals undergoing various forms of
repeated stress. He�s looking in the hippocampus. Imaging studies
have shown that this area, like the prefrontal cortex and, more
recently, the amygdala, shrinks in people with recurrent
depression.
Although it is, he says, "just the tip of
the iceberg," the hippocampus is the region of the depression
circuit that has been best studied�and linked longest to stress. In
the past decade studies have shown that prolonged stress kills
hippocampal cells, precipitating cognitive decline.
McEwen himself has documented that several
different kinds of stress�including the psychosocial stress of
being a subordinate among group-living animals, the stress of being
physically restrained from moving about�can cause hippocampal cells
to atrophy and retract their dendrites, presumably to make fewer
connections. Others have found the same effects on animals from the
stress of social isolation and, among infants, even spells of
deprivation of maternal care. McEwen has also found that
stress can suppress nerve cell growth in a part of the hippocampus
just recently shown to be able to renew nerve cells in adult
life. He�s trying to nail down what is cause and what is
effect.
"So far," McEwen offers, "all we know
about depression and atrophy of these brain structures is that it�s
seen in people who have a long history of recurrent depressive
illness, which may be a neurodegenerative disease. It may be that
those changes can not be reversed."
However, they may be preventable earlier on
in the course of depression, by timely use of an appropriate drug.
"We�ve begun to look at this, reports Yale�s Ronald Duman. ""And we
have found that antidepressant treatments are in fact able to
induce the genesis of neurons."
Freud 1, Neurobiology 1
For many neurobiologists, behavioral
plasticity is only half the new story on depression. The other part
is the degree to which early experience can establish a whole
lifelong pattern of brain activity. New research both in animals
and in people demonstrates that stress early in life permanently
sensitizes neurons and receptors throughout the central nervous
system so that they perpetually overrespond to stress.
At the most recent meeting of the Society
for Neuroscience, for example, research psychologist Christine
Heim, Ph.D., reported that sexual abuse in girls before puberty
creates hyperactivity of the stress-hormone system headquartered in
the brain�s hypothalamus. And that makes them subject to depression
as adults. "This is the first human study to report persistent
changes in the reactivity of the hypothalamus-pituitary-adrenal
axis among adult survivors of early trauma," she points
out.
Heim so far has studied eight depressed
women with a documented history of childhood abuse, seven women who
also experienced childhood abuse but who do not have depression,
and seven control women who were never exposed to such early life
stress and who have never been depressed. In the neurobiology lab
at Emory University, she tracked the chemical footprints of stress
reactivity, in both brain and body, in all 22 women after applying
mild stress�assigning them to make a brief speech and perform
mental arithmetic in front of a small audience.
Normally, when a threat to physical or
psychological well-being is detected, the hypothalamus amplifies
production of corticotropin-releasing factor (CRF), which induces
the pituitary gland to secrete ACTH, which then instructs the
adrenal glands to step up production of cortisol. Early trauma,
Heim found, leads to chronic overactivation of the system. CRF,
many researchers are finding, acts of various brain sites to create
the symptoms of depression.
All of the women who experienced early trauma
reacted to the experimental stress with elevated levels of stress
hormones, although the hormone levels were highest in those with
current major depression. Such studies are leading researchers to a
new model of depression, one they call the diathesis-stress model.
Simply put, some inherited factor�maybe a flawed gene for BDNF, or
individual differences in PFC activity�creates the biological
vulnerability for major depression.
Then some early stressful experience�such
as parental neglect or physical or sexual abuse�sets up the brain
to permanently overreact to environmental pressures. Then even
small degrees of later stress provoke an outpouring of stress
hormones, such as CRF and cortisol, throughout the brain (and
body).
These hormones act directly on multiple
sites to produce the behavioral symptoms of depression�the
vegetative state, the sleep disturbances, the cognitive dullness,
the loss of pleasure. They push the amygdala into overdrive,
churning out the negative emotions that steer the depression�s
severity and add a twist of anxiety. And, as if that weren�t
enough, they magnify the effects of the neurotransmitter glutamate
so that it overstimulates neurons until their dendrites collapse
and shrink up.
The moral of the story: Early life
experience counts. Not because it creates oral fixations or other
such fictions. It shapes wiring patterns in the brain and sets the
sensitivity of the molecular machinery, such as production of nerve
growth factors, behind nerve-cell operations.
It�s Not All In the Head
While disparate biological changes suggest
that there are different types of depressions�some seeming to arise
spontaneously from within, others reflecting heightened reactivity
to life events�all depression is more than an affliction from the
neck up. It is a whole-body disorder.
At Columbia University, where he is a
professor of psychiatry, Alexander Glassman, M.D., had been
studying the cardiac effects of antidepressant drugs when reports
began to trickle in confirming what he had suspected�that
depression makes heart disease particularly deadly. But it wasn�t
clear how much of a role cigarette smoking played; the depressed
are especially apt to smoke, and smoking leads to heart
disease.
So Glassman teamed up with epidemiologists
following thousands of people for over a decade. In 1993 the group
reported that, even after they controlled for smoking, depression
essentially multiplies the malignity of heart disease,
substantially increasing the risk of sudden death within the next
year. The report dropped an even bigger bombshell; it showed that
healthy people who are struck by depression are more
likely than their counterparts without the mental
ailment to develop heart disease about 10 years down the
road. Just because they once got depressed.
"There are two things we can say
without any hesitancy," says Glassman. "If you�re 45, in perfect
health, and depressed, you�re somewhere between 50% and 100% more
likely to have a heart attack than if you weren�t depressed. That�s
big. And if you have a heart attack and then get depressed, whether
you simply get some symptoms of depression or the full diagnosis,
over the next 18 months you are three and a half times more likely
to die. That�s even bigger."
The numbers add up. There are roughly
500,000 heart attacks a year in the U.S. And 20% of heart attack
victims develop depression.
What puts the head and the heart on a
collision course are, likely, blood platelets, which play a key
role in the propensity of blood to form clots. Platelets turn out
to be stickier in those who are depressed. At Emory University in
Atlanta, home of one of the world�s leading neurobiology labs,
Dominique Musselman, M.D., has shown that the platelets of
depressed people are hair-trigger responsive to activation signals,
aggregating when they should be flowing.
A decade ago, the thinking was that heart
attacks occurred when cholesterol-laden plaques formed on coronary
artery walls and, over time, grew large enough to block blood flow
in the artery. Today it�s known that heart attacks occur only when
a crack develops in the artery lining that covers the slow-growing
plaque. Then platelets are suddenly drawn to the site, where they
adhere to the exposed artery wall and rope in even more platelets.
Clotting occurs within minutes, choking off blood flow to the
heart.
Bones of Contention
The somatic changes of psychological
depression go bone deep. Literally. The hormonal abnormalities that
mark the disorder, particularly elevated body levels of cortisol
produced by the adrenal glands, also rob the skeleton of calcium.
The result: osteoporosis on a highly accelerated
schedule.
A team of researchers at the National
Institutes of Health has found that depressed premenopausal women
develop bones as porous as those of postmenopausal women. And the
leaching of mineral from bone persists despite treatment with
antidepressant drugs.
Led by David Michaelson, M.D., the
researchers reported that bone mineral density was, on average, 6%
lower in the spine among 24 depressed women than among 24 controls.
And in the hip, it was 10% to 14% lower among the depressed
women�decrements that set women up for hip fractures.
"Once lost," Michaelson observes, "bone
density is difficult to regain." It takes years, plus a modicum of
physical activity and a calcium-rich diet. But it probably never
returns to normal in depression, since the disorder tends to
recur�and depressed people tend to be physically inactive and eat
poorly.
It�s not that chronic depression doesn�t
create a huge psychological burden. But it�s becoming increasingly
clear, says Columbia�s Glassman, that "depression is an illness
with very real and dangerous physical concomitants."
Sick, Not Sad?
The new corporeality of "mental" illness
is perhaps most daringly embodied in the work of Bruce Charlton,
M.D., a research psychiatrist in the department of psychology at
the University of Newcastle in England. Depression, Charlton
provocatively contends, doesn�t just have physical concomitants; it
is wholly a physical disorder, one that is misinterpreted by the
brain. Sickness is read as sadness.
The low mood is a secondary response, a
product of physical malaise, the same malaise�the lack of energy,
sleepiness, slowness of movement, lack of pleasurable appetites
(including sex), inability to concentrate and think clearly�one
gets when, say, the flu strikes. "The trouble with malaise is that
you don't necessarily know you've got it, and you blame yourself
for your condition of low performance," he says.
But it is the body�s way of withdrawing
(think of a wounded animal) to conserve energy and minimize risk,
an "evolved pattern of behavior" mediated by the immune system. "In
fact," he says, "major depressive disorder is sickness behavior
inappropriately activated and sustained."
Charlton subscribes to the model of
emotions put forth by the University of Iowa�s Antonio Damasio,
M.D.�that feelings are the brain�s representation of what�s going
on in the body. But, he says, sadness and happiness do not
correspond to specific body states. Instead, they are "catch-all
names given to aversive and gratifying states, end products of more
primary emotions."
Still, the prevailing body state, the
malaise, colors all incoming perceptions and stamps them "aversive"
as they are encoded in memory. Recall, then, summons up malaise, as
does thinking about the future. To the extent the malaise
continues, patients are stuck, unable to even imagine anything that
makes them feel motivated and energetic. Bleakness! Despair!
Depression!
According to this view, antidepressants,
notably the tricyclics, possibly Prozac, probably work to the
degree that they are analgesics! "Antidepressants do not make
people happy," Charlton insists. They treat the malaise, the state
of unpleasantness. In so doing they "remove a significant obstacle
to happiness. The effect of antidepressants on mood is no more
remarkable than the fact that it is easier to be happy without a
headache." Imagine�aspirin as a remedy for the blues!
Charlton is not alone in disputing the way
antidepressant drugs are believed to work. British psychiatrist
David Healy, a card-carrying psychopharmacologist, in his book The
Antidepressant Era (Harvard, 1998) contends that these agents
are falsely presented as specific to depression. The idea that
depression is a single specific disorder, Healy says, was
created largely by drug companies with a
product�antidepressants�to sell. He argues instead that
"depression" is even more than a disorder of the whole body; it�s a
disorder of the whole person, existential or social distress marked
by unhappiness and hopelessness. It is cast into physical
symptoms�precisely because they have been made fashionable,
sanctioned and publicized by today�s medical-industrial
complex.
Therapy: Stripped Down and Revved
Up
While debate has raged for decades over
the relative contributions of nature and nurture to creating
depression, and the relative merits of drug and psychotherapy to
relieve it, therapy itself is evolving in ways that eventually
promise to make the old issues obsolete. Consider the case of
meditation, which is now being tested as both a preventive and a
treatment for depression. It isn�t specific for depression. Yet it
may reverse changes in the brain that are specific to depression.
Is it treatment of an organ? Or of the whole person?
At Cambridge University in England, John
Teasdale, M.D., has been testing meditation on recurrently
depressed persons who are currently free of the ailment. The goal
is to reduce the risk of future relapse. "Our results are
encouraging," Teasdale teases, refusing to say more until his study
report is accepted for publication in a scholarly
journal.
In the U.S., Wisconsin�s Richard Davidson
is also testing meditation, in this case measuring its effects on
brain function. He is specifically looking to see whether it
activates the left PFC or deactivates the right PFC, or
both.
Two other new therapies, both inventions
of the mid-1990s, are essentially adaptations of earlier
treatments. And both, like meditation, have a stripped-down,
tightly focused quality.
One is transcranial magnetic stimulation
(TMS), a vastly defanged cousin of the extreme yet often-effective
electroconvulsive therapy. In TMS, a hand-held electromagnetic coil
is placed on the scalp and a series of tiny pulses are released
that prompt the cortical neurons directly underneath to fire. In
one placebo-controlled study, where TMS was applied over the left
prefrontal cortex in daily 20-minute sessions for two weeks,
patients experienced a measureable lessening of depressive
symptoms.
The therapy is too new for researchers to
know yet what the best dose is, exactly where to apply the current
and how often. But they are confident it causes no side effects.
There are no convulsions, no loss of consciousness, no memory
gaps�just a tiny tingle. It is now being tested around the country
as an outpatient treatment for both unipolar and bipolar
depression.
At the National Institute of Mental
Health, where researchers first developed the technique as "a
neuropsychiatric tool for the 21st century," investigators have
found that TMS produces changes in brain hormones suggestive of a
tamping down of hypothalamic overactivity. But its antidepressant
action may have more to do with the possibility that the treatment
stimulates neuronal plasticity; researchers now know that is what
ECT does, forging the connections from one nerve cell to the next
that allow for behavioral change.
Behavioral change is the unambiguous goal
of behavioral activation (BA), a treatment developed by
psychologist Neil S. Jacobson, Ph.D. It turns clients�he rejects
the term "patients" and all "defect" models of depression,
whether the defect is in brain chemistry or patterns of
thinking�into miniscientists, prompting them to observe and
identify aspects of their daily life that influence mood, to set
workable goals, then to make small changes on a daily basis,
acquiring the skills they need to solve their own life
problems.
"BA takes a contextual view of
depression," says Jacobson, professor of psychology at the
University of Washington. It sees depression as a signal that
"something is awry in the person�s life, that what is wrong is the
life and not the person." BA helps people avoid making things worse
by retreating from the world, "something that�s natural to do when
you�re feeling depressed" but that cuts off needed sources of
pleasure.
In a study of 149 depressed persons, BA
proved as effectve as full-blown cognitve therapy in reducing
depressive symptoms. Although it didn't even
attempt to alter clients� thinking, BA
nevertheless decreased negative thinking. It significantly lowered
clients� tendencies to attribute problems or negative events to
factors that are internal as opposed to situational ("I�m
stupid."), enduring ("I was born this way."), and
all-encompassing (I can�t do anything right.")�attributional styles
that catapult people into depression.
Having performed as well as cognitive
therapy, BA has now been put to the test against an antidepressant
drug, the SSRI Paxil. "Our current trial is looking even better
than the last one," Jacobson confides. "BA is working better in the
short run and at least as well as Paxil." Long-term data, however,
aren�t in yet.
Jacobson has his fingers crossed.
"Antidepressants can be more of a problem than a solution, because
at times when people feel good they lose their motivation to change
their lives. When the drug effect wears off, as it does eventually,
they still have the same life problems."
Plasticity Regained
Whatever pathways depression takes through
the brain and the body, it is still experienced by sufferers as a
disorder of the whole person, which is why its pain has always been
so hard to locate. As a result, how depression is seen by
psychologists and psychiatrists, how they explain it to you and me,
and how patients understand their own disorder�all influence not
only what symptoms patients complain of, but what they are willing
to do about them.
Fashions in thinking about depression make
a measurable difference to recovery. "We have, before applying
standard treatments, looked at clients� theories of why they are
depressed," reports Michael Addis, Ph.D., a psychologist now at
Clark University in Worcester, Massachusetts, who studied with
Jacobson�s group in Seattle. "Their theories are predictive of the
outcome of treatment."
What is available to clients as
explanation is the very stuff psychologists and psychiatrists talk
about. The culture has become both more psychological-minded and
more biological-minded. As a result, Addis has heard clients say
things like, "My doctor said this is a chemical imbalance, so why
are you talking to me about doing pleasurable
activities?"
He urges professionals to understand what
patients think of their own psychopathology. "We don�t know what
our theories mean to individuals. We say �chemical imbalance.� To a
patient that means, �I�m damned.� Our theories are not
neutral."
Which is why Peter Kramer, who usually
prescribes both psychotherapy and drug therapy, ponders "which is
the umbrella concept?" Is the brain a biological organ and
psychotherapy another way to influence the brain? This is the view
the field of psychiatry is moving towards.
Or is drug therapy an adjunct to
psychotherapy? "This is my model," he says. "Medication is one way
of helping patients broaden their perspective." In other words,
it�s a way to restore what makes people most human�our remarkable
capacity for meeting life�s ever-changing demands.
Copyright 1999 Hara Marano. All rights
reserved. HMarano@aol.com
Back to Articles page